Cantargia AB (publ) (CANTA.ST)
SEK 1.83
(1.05%)
SEK 1.83
(1.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 290.01 Million SEK | -23.61% |
| 2022 | 379.65 Million SEK | 3.16% |
| 2021 | 368.01 Million SEK | 112.34% |
| 2020 | 173.31 Million SEK | 56.74% |
| 2019 | 110.57 Million SEK | 19.19% |
| 2018 | 92.77 Million SEK | 55.14% |
| 2017 | 59.8 Million SEK | 33.64% |
| 2016 | 44.74 Million SEK | 162.94% |
| 2015 | 17.01 Million SEK | 109.7% |
| 2014 | 8.11 Million SEK | 1.73% |
| 2013 | 7.97 Million SEK | 126.83% |
| 2012 | 3.51 Million SEK | 3.13% |
| 2011 | 3.41 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 43.82 Million SEK | 8.59% |
| 2024 Q1 | 40.35 Million SEK | -42.9% |
| 2023 Q3 | 78.7 Million SEK | 25.68% |
| 2023 Q1 | 77.55 Million SEK | -11.68% |
| 2023 Q4 | 70.68 Million SEK | -10.19% |
| 2023 Q2 | 62.62 Million SEK | -19.25% |
| 2023 FY | 284.31 Million SEK | -25.11% |
| 2022 Q3 | 74.22 Million SEK | -22.68% |
| 2022 FY | 379.65 Million SEK | 3.16% |
| 2022 Q1 | 121.6 Million SEK | 17.49% |
| 2022 Q4 | 87.81 Million SEK | 18.3% |
| 2022 Q2 | 96 Million SEK | -21.05% |
| 2021 Q2 | 86.59 Million SEK | 18.34% |
| 2021 Q1 | 73.17 Million SEK | 31.07% |
| 2021 Q3 | 104.74 Million SEK | 20.96% |
| 2021 Q4 | 103.5 Million SEK | -1.19% |
| 2021 FY | 368.01 Million SEK | 112.34% |
| 2020 FY | 173.31 Million SEK | 56.74% |
| 2020 Q1 | 39.93 Million SEK | 12.77% |
| 2020 Q2 | 37.65 Million SEK | -5.71% |
| 2020 Q3 | 39.89 Million SEK | 5.94% |
| 2020 Q4 | 55.82 Million SEK | 39.94% |
| 2019 Q1 | 23.66 Million SEK | -15.39% |
| 2019 FY | 110.57 Million SEK | 19.19% |
| 2019 Q4 | 35.41 Million SEK | 34.64% |
| 2019 Q3 | 26.3 Million SEK | 4.39% |
| 2019 Q2 | 25.19 Million SEK | 6.49% |
| 2018 Q3 | 21.25 Million SEK | -25.19% |
| 2018 Q1 | 15.24 Million SEK | -6.21% |
| 2018 Q4 | 27.96 Million SEK | 31.59% |
| 2018 Q2 | 28.4 Million SEK | 86.28% |
| 2018 FY | 92.77 Million SEK | 55.14% |
| 2017 FY | 59.8 Million SEK | 33.64% |
| 2017 Q3 | 11.05 Million SEK | -27.7% |
| 2017 Q2 | 15.29 Million SEK | -11.01% |
| 2017 Q1 | 17.18 Million SEK | 5.86% |
| 2017 Q4 | 16.25 Million SEK | 47.03% |
| 2016 Q2 | 7.92 Million SEK | -2.16% |
| 2016 Q3 | 12.48 Million SEK | 57.55% |
| 2016 Q4 | 16.23 Million SEK | 30.03% |
| 2016 FY | 44.74 Million SEK | 162.94% |
| 2016 Q1 | 8.1 Million SEK | 65.53% |
| 2015 Q4 | 4.89 Million SEK | 56.43% |
| 2015 FY | 17.01 Million SEK | 109.7% |
| 2015 Q3 | 3.12 Million SEK | -42.42% |
| 2015 Q2 | 5.43 Million SEK | 54.56% |
| 2015 Q1 | 3.51 Million SEK | 44.4% |
| 2014 FY | 8.11 Million SEK | 1.73% |
| 2014 Q1 | 1.86 Million SEK | 140.55% |
| 2014 Q3 | 1.97 Million SEK | 8.01% |
| 2014 Q4 | 2.43 Million SEK | 22.94% |
| 2014 Q2 | 1.83 Million SEK | -1.9% |
| 2013 FY | 7.97 Million SEK | 126.83% |
| 2013 Q4 | 776.76 Thousand SEK | 0.0% |
| 2012 FY | 3.51 Million SEK | 3.13% |
| 2011 FY | 3.41 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 5.56% |
| Ziccum AB (publ) | 27.87 Million SEK | -940.308% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -1668.289% |
| BioArctic AB (publ) | 89.62 Million SEK | -223.582% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -580.28% |
| Mendus AB (publ) | 129.13 Million SEK | -124.581% |
| Genovis AB (publ.) | 88.19 Million SEK | -228.829% |
| Intervacc AB (publ) | 79.78 Million SEK | -263.498% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -1540.089% |
| Active Biotech AB (publ) | 44.8 Million SEK | -547.229% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -113.386% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -248.708% |
| Aptahem AB (publ) | 10.01 Million SEK | -2796.421% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 9.794% |
| Kancera AB (publ) | 63.07 Million SEK | -359.782% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -115.315% |
| Fluicell AB (publ) | 28.61 Million SEK | -913.443% |
| Saniona AB (publ) | 1.07 Million SEK | -26828.227% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -3898.029% |
| Biovica International AB (publ) | 133.72 Million SEK | -116.881% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -1365.472% |
| AcouSort AB (publ) | 25.87 Million SEK | -1020.795% |
| Xintela AB (publ) | 57.31 Million SEK | -405.997% |
| Abliva AB (publ) | 27.86 Million SEK | -940.756% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -49.88% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -5154.883% |
| OncoZenge AB (publ) | 15.9 Million SEK | -1723.433% |
| Amniotics AB (publ) | 29.07 Million SEK | -897.582% |
| 2cureX AB (publ) | 36.51 Million SEK | -694.175% |
| CombiGene AB (publ) | 44.14 Million SEK | -556.978% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -1879.233% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 80.847% |
| Camurus AB (publ) | 1.05 Billion SEK | 72.631% |
| Corline Biomedical AB | 30.16 Million SEK | -861.34% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -399.762% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -3890.327% |
| I-Tech AB | 40.14 Million SEK | -622.37% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 66.255% |
| Cyxone AB (publ) | 28.21 Million SEK | -927.919% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -165.175% |
| Biosergen AB | 26.8 Million SEK | -981.79% |
| NextCell Pharma AB | -576.01 Thousand SEK | 50448.513% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -59.583% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -923.842% |
| Nanologica AB (publ) | 69.88 Million SEK | -314.98% |
| SynAct Pharma AB | 224.49 Million SEK | -29.186% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -556.504% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -1110.711% |
| LIDDS AB (publ) | 27.75 Million SEK | -945.031% |
| Lipum AB (publ) | 37.3 Million SEK | -677.38% |
| BioInvent International AB (publ) | 441.4 Million SEK | 34.297% |
| Alzinova AB (publ) | 36.39 Million SEK | -696.838% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -0.094% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -3591.536% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -152.029% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -1224.581% |
| Simris Alg AB (publ) | 38.64 Million SEK | -650.523% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -102.828% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 18.904% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -161.479% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -1872.905% |